R. Stupp, W. P. Mason, M. J. Van-den-bent, M. Weller, and B. Fisher, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, vol.352, pp.987-996, 2005.

B. Kaur, F. W. Khwaja, E. A. Severson, S. L. Matheny, and D. J. Brat, Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis, Neuro Oncol, vol.7, pp.134-153, 2005.

C. Xu, X. Wu, and J. Zhu, VEGF promotes proliferation of human glioblastoma multiforme stem-like cells through VEGF receptor 2, ScientificWorldJournal, p.417413, 2013.

R. Mentlein, F. Forstreuter, H. M. Mehdorn, and J. Held-feindt, Functional significance of vascular endothelial growth factor receptor expression on human glioma cells, J Neurooncol, vol.67, pp.9-18, 2004.

H. Huang, J. Held-feindt, R. Buhl, H. M. Mehdorn, and R. Mentlein, Expression of VEGF and its receptors in different brain tumors, Neurol Res, vol.27, pp.371-377, 2005.

A. K. Lucio-eterovic, Y. Piao, and J. F. De-groot, Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy, Clin Cancer Res, vol.15, pp.4589-4599, 2009.

M. Chahal, Y. Xu, D. Lesniak, K. Graham, and K. Famulski, MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib, Neuro Oncol, vol.12, pp.822-833, 2010.

H. S. Friedman, M. D. Prados, P. Y. Wen, T. Mikkelsen, and D. Schiff, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol, vol.27, pp.4733-4740, 2009.

T. Cloughesy, FDA accelerated approval benefits glioblastoma, Lancet Oncol, vol.11, p.1120, 2010.

D. A. Reardon, S. Turner, K. B. Peters, A. Desjardins, and S. Gururangan, A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma, J Natl Compr Canc Netw, vol.9, pp.414-427, 2011.

R. Henriksson, A. Bottomley, W. Mason, F. Saran, and W. Wick, Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM), J Clin Oncol, 2013.

T. T. Batchelor, D. G. Duda, E. Di-tomaso, M. Ancukiewicz, and S. R. Plotkin, Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma, J Clin Oncol, vol.28, pp.2817-2823, 2010.

T. T. Batchelor, P. Mulholland, B. Neyns, L. B. Nabors, and M. Campone, Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma, J Clin Oncol, vol.31, pp.3212-3218, 2013.

P. Y. Wen, D. R. Macdonald, D. A. Reardon, T. F. Cloughesy, and A. G. Sorensen, Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group, J Clin Oncol, vol.28, pp.1963-1972, 2010.

M. Law, S. Yang, H. Wang, J. S. Babb, and G. Johnson, Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging, AJNR Am J Neuroradiol, vol.24, pp.1989-1998, 2003.

R. Francescone, S. Scully, B. Bentley, W. Yan, and S. L. Taylor, Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation, J Biol Chem, vol.287, pp.24821-24831, 2012.

D. Morvan, A. Demidem, J. Papon, and J. C. Madelmont, Quantitative HRMAS proton total correlation spectroscopy applied to cultured melanoma cells treated by chloroethyl nitrosourea: demonstration of phospholipid metabolism alterations, Magn Reson Med, vol.49, pp.241-248, 2003.

O. Beckonert, H. C. Keun, T. M. Ebbels, J. Bundy, and E. Holmes, Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts, Nat Protoc, vol.2, pp.2692-2703, 2007.

M. Cuperlovi?-culf, D. A. Barnett, A. S. Culf, and I. Chute, Cell culture metabolomics: applications and future directions, Drug Discov Today, vol.15, pp.610-621, 2010.

M. N. Triba, A. Starzec, N. Bouchemal, E. Guenin, and G. Y. Perret, Metabolomic profiling with NMR discriminates between biphosphonate and doxorubicin effects on B16 melanoma cells, NMR Biomed, vol.23, pp.1009-1016, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00609861

J. Kronthaler, G. Gstraunthaler, and C. Heel, Optimizing high-throughput metabolomic biomarker screening: a study of quenching solutions to freeze intracellular metabolism in CHO cells, OMICS, vol.16, pp.90-97, 2012.

T. Mosmann, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J Immunol Methods, vol.65, pp.55-63, 1983.

F. Delaglio, S. Grzesiek, G. W. Vuister, G. Zhu, and J. Pfeifer, NMRPipe: a multidimensional spectral processing system based on UNIX pipes, J Biomol NMR, vol.6, pp.277-293, 1995.

J. Trygg and S. Wold, Orthogonal Projections to Latent Structures, J Chemometrics, vol.16, pp.119-128, 2002.

P. Knizetova, J. Ehrmann, A. Hlobilkova, I. Vancova, and O. Kalita, Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay, Cell Cycle, vol.7, pp.2553-2561, 2008.

S. Grau, J. Thorsteinsdottir, L. Von-baumgarten, F. Winkler, and J. C. Tonn, Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells, J Neurooncol, vol.104, pp.103-112, 2011.

P. Hamerlik, J. D. Lathia, R. Rasmussen, C. Caldas, and R. A. Kauppinen, Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth, J Exp Med, vol.209, pp.507-520, 2012.

L. Von-baumgarten, D. Brucker, A. Tirniceru, Y. Kienast, and S. Grau, Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells, Clin Cancer Res, vol.17, pp.6192-6205, 2011.

O. Keunen, M. Johansson, A. Oudin, M. Sanzey, and S. A. Rahim, Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma, Proc Natl Acad Sci U S A, vol.108, pp.3749-3754, 2011.

P. Kunkel, U. Ulbricht, P. Bohlen, M. A. Brockmann, and R. Fillbrandt, Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2, Cancer Res, vol.61, pp.6624-6628, 2001.

M. Pàez-ribes, A. E. Hudock, J. Takeda, T. Okuyama, and H. , Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis, Cancer Cell, vol.15, pp.220-231, 2009.

M. C. Chamberlain, Radiographic patterns of relapse in glioblastoma, J Neurooncol, vol.101, pp.319-323, 2011.

A. Wick, N. Dörner, N. Schä-fer, S. Hofer, and S. Heiland, Bevacizumab does not increase the risk of remote relapse in malignant glioma, Ann Neurol, vol.69, pp.586-592, 2011.

J. L. Griffin, K. K. Lehtimä-ki, P. K. Valonen, O. H. Gröhn, and M. I. Kettunen, Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapyinduced programmed cell death, Cancer Res, vol.63, pp.3195-3201, 2003.

J. L. Griffin, C. Blenkiron, P. K. Valonen, C. Caldas, and R. A. Kauppinen, Highresolution magic angle spinning 1H NMR spectroscopy and reverse transcription-PCR analysis of apoptosis in a rat glioma, Anal Chem, vol.78, pp.1546-1552, 2006.

X. Pan, M. Wilson, C. Mcconville, T. N. Arvanitis, and J. L. Griffin, Increased unsaturation of lipids in cytoplasmic lipid droplets in DAOY cancer cells in response to cisplatin treatment, Metabolomics, vol.9, pp.722-729, 2013.

E. J. Delikatny, W. A. Cooper, S. Brammah, N. Sathasivam, and D. C. Rideout, Nuclear magnetic resonance-visible lipids induced by cationic lipophilic chemotherapeutic agents are accompanied by increased lipid droplet formation and damaged mitochondria, Cancer Res, vol.62, pp.1394-1400, 2002.

L. Mirbahai, M. Wilson, C. S. Shaw, C. Mcconville, and R. D. Malcomson, Lipid biomarkers of glioma cell growth arrest and cell death detected by 1 H magic angle spinning MRS, NMR Biomed, vol.25, pp.1253-1262, 2012.

O. Martinho, R. Silva-oliveira, V. Miranda-gonçalves, C. C. Almeida, and J. R. , In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas, Transl Oncol, vol.6, pp.187-196, 2013.

K. K. Lehtimä-ki, P. K. Valonen, J. L. Griffin, T. H. Väisä-nen, and O. H. Gröhn, Metabolite changes in BT4C rat gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death as studied by 1H NMR spectroscopy in vivo, ex vivo, and in vitro, J Biol Chem, vol.278, pp.45915-45923, 2003.

G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak, Vascular endothelial growth factor (VEGF) and its receptors, FASEB J, vol.13, pp.9-22, 1999.

C. J. Robinson and S. E. Stringer, The splice variants of vascular endothelial growth factor (VEGF) and their receptors, J Cell Sci, vol.114, pp.853-865, 2001.

H. Vink and B. R. Duling, Capillary endothelial surface layer selectively reduces plasma solute distribution volume, Am J Physiol Heart Circ Physiol, vol.278, pp.285-289, 2000.

U. Adamcic, K. Skowronski, C. Peters, J. Morrison, and B. L. Coomber, The effect of bevacizumab on human malignant melanoma cells with functional VEGF/ VEGFR2 autocrine and intracrine signaling loops, Neoplasia, vol.14, pp.612-623, 2012.

J. Y. Jeon, I. Kovanlikaya, J. A. Boockvar, X. Mao, and B. Shin, Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton MR spectroscopic imaging study, AJNR Am J Neuroradiol, vol.33, pp.2095-2102, 2012.

E. M. Ratai, Z. Zhang, B. S. Snyder, J. L. Boxerman, and Y. Safriel, Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677, Neuro Oncol, vol.15, pp.936-944, 2013.

H. Kim, C. Catana, E. M. Ratai, O. C. Andronesi, and D. L. Jennings, Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma, Cancer Res, vol.71, pp.3745-3752, 2011.